Talents: HR Flash
The European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration!
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
Jesper Ericsson named new Chief Executive Officer by Symcell Sverige AB
Symcel announced that Jesper Ericsson has joined Symcel as Chief Executive Officer.
Polpharma: Making biologics economic
After having set up a R&D hub for the biomanufacturing of clinical trial supplies in Gdansk, Polpharma is expanding its European footprint with a €100m investment in Warsaw. Several take-overs previously made the company a one-stop shop for biomanufacturing. European Biotechnology spoke with Federico Pollano, Director Contract Manufacturing and Business Development at the CDMO and biosimilars maker, about Polpharma’s strategy and expansion of biologics production.
MDx Health hires Michael Brawer as CMO
Belgian diagnostics company MDxHealth SA has appointed Michael K. Brawer, MD as Chief Medical Officer to prepare the company for growth in H2/17 and beyond. The urologist and former professor of urology and pathology has over 25 years of experience in the industry leading clinical affairs in urology for diagnostic and pharmaceutical companies. Before joining MDx Health, Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialisation of Myriad’s prognostic prostate cancer assay. Prior to that, he held senior positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. "Dr. Brawer’s arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase", commented Dr. Jan Groen, CEO, MDxHealth.
New CFO for Pharmalink
Swedish specialty pharmaceutical company Pharmalink AB Stockholm has Fredrik Johansson as new Chief Financial Officer.
Orchard Therapeutics appoints Mark Rothera as CEO
Gene therapy specialist Orchard Therapeutics (London) has appointed Mark Rothera as President and Chief Executive Officer, a specialist for the commercialisation of novel treatments and business development.
IP: Brexit and patents
On 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
Uniqure’s new COO to oversee GMP
Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Biosimilars labelling
EuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency for the label.
Benefits and challenges in pharma innovation
We are living in a world of cutting-edge science, which holds the potential to transform the landscape for patients living with common and rare diseases within the next five years. This is of particular importance as we face a demographic evolution that will see an already-aging population expand significantly and rapidly across the globe.